About
This information supports the Siliq Dosing Calculator, a tool for healthcare professionals to visualize the standard administration schedule for Siliq® (brodalumab). It helps in planning the induction and maintenance phases based on the FDA-approved prescribing information. This content does not replace clinical judgment or the full prescribing information.
Outputs
Upon selecting a treatment start date, the calculator generates a detailed dosing schedule that includes:
- Dose Number: Sequential numbering for each administration.
- Treatment Phase: Clear labeling of “Induction” and “Maintenance” phases.
- Week Number: The corresponding week of treatment (e.g., Week 0, 1, 2, 4).
- Administration Date: The specific calendar date for each scheduled subcutaneous injection.
How to Use
To generate a dosing schedule, follow these simple steps:
- Step 1: Locate the input field labeled “Treatment Start Date (Week 0)”.
- Step 2: Click the field and select the patient’s intended first administration date from the calendar.
- Step 3: The dosing schedule will automatically generate and appear on the screen.
Dosing Overview
The calculator follows the standard dosing regimen for Siliq in adults with moderate-to-severe plaque psoriasis.
- Dose: 210 mg administered via subcutaneous injection.
- Induction Phase: One 210 mg injection at Week 0, Week 1, and Week 2.
- Maintenance Phase: One 210 mg injection every 2 weeks thereafter.
Switching
The Prescribing Information does not provide specific instructions for switching patients from other systemic therapies or biologics to Siliq. When transitioning a patient, healthcare providers should use clinical judgment, considering the pharmacokinetics (e.g., half-life) of the previous therapy to determine the appropriate timing to initiate Siliq. The standard induction dosing schedule (Weeks 0, 1, and 2) should be used upon starting Siliq.
Missed Dose
If a patient misses a dose of Siliq, they should be instructed to inject it as soon as they remember. The subsequent dose should then be administered at the regularly scheduled time. If necessary, a new, consistent bi-weekly schedule can be established based on the date of the most recent injection.
Safety Alerts
Suicidal ideation and behavior, including completed suicides, have occurred in patients treated with Siliq. Siliq is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the SILIQ REMS Program. Other important safety information includes warnings for Crohn’s Disease and risk of infections. Always consult the full Prescribing Information for a complete list of contraindications, warnings, and precautions.
Frequently Asked Questions (FAQ)
1. How many doses does the calculator schedule in total?
The calculator generates a schedule for the first 19 doses, which includes the 3-dose induction phase and the first 16 maintenance doses, covering approximately the first 34 weeks of treatment.
2. Does the calculator adjust the schedule for a missed dose?
No. The tool generates an ideal, uninterrupted dosing schedule based on the selected start date. It does not have functionality to account for missed or delayed administrations.
3. Can I use this calculator for pediatric patients?
No. The safety and effectiveness of Siliq have not been established in pediatric patients. The calculator is intended for the approved adult dosing regimen.
4. What happens if I select a date in the past?
The calculator will generate a schedule based on that past date. The output will show dates that have already passed, which can be useful for auditing or reviewing a patient’s past dosing schedule.
5. Does the tool provide dose adjustments for renal or hepatic impairment?
No, the tool only calculates the standard 210 mg dose. According to the prescribing information, no dose adjustment is needed for mild to moderate renal or mild hepatic impairment. Siliq has not been studied in severe impairment.
6. Is this calculator a substitute for the official Prescribing Information?
Absolutely not. This tool is for convenience and educational purposes only. It is not a substitute for clinical judgment, and all information must be verified against the full, most current Prescribing Information before making clinical decisions.
7. What is the maintenance dosing frequency shown by the calculator?
Following the induction phase at Weeks 0, 1, and 2, the calculator schedules maintenance doses every 2 weeks, starting at Week 4.
8. Can I print the generated dosing schedule?
The tool does not have a dedicated print button. However, you can use your web browser’s built-in print function (Ctrl+P or Cmd+P) to print the page, which will include the generated schedule.
References
- Siliq (brodalumab) Prescribing Information. Bausch Health US, LLC. U.S. Food and Drug Administration. Revised: January 2024. Available here.
- Siliq® (brodalumab) HCP Website. Bausch Health. Accessed here.
- Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029-1072. Available here.
- Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366(13):1181-1189. Available on PubMed.
